Thrombopoietin Receptor Agonists: A Critical Review

William B. Mitchell, James B. Bussel

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Thrombopoietic agents have created a paradigm shift in the management of chronic or poorly responsive immune thrombocytopenia (ITP). There are ample randomized, placebo-controlled trial data, as well as long-term data gathered for more than 5 years; short-term efficacy and safety are well documented and long-term efficacy and safety data are emerging. The purpose of this review will be to focus critically on what we know or do not know at this point about these agents. We review the evolution, efficacy and clinical use, side effects, special populations, and off-target effects of the thrombopoietic agents.

Original languageEnglish (US)
Pages (from-to)46-52
Number of pages7
JournalSeminars in hematology
Issue number1
StatePublished - Jan 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Thrombopoietin Receptor Agonists: A Critical Review'. Together they form a unique fingerprint.

Cite this